All‐cause mortality or liver‐related morbidity · people with chronic hepatitis C
Peginterferon plus ribavirin showed no clear difference in liver‐related morbidity plus all‐cause mortality compared with non‐pegylated interferon plus ribavirin (low certainty).
1 finding from 1 review
OR 1.14 [0.38, 3.42]
1789 participants
Low
Discontinuation of medication due to adverse events · people with chronic hepatitis C
Peginterferon plus ribavirin showed no clear difference in adverse events leading to treatment discontinuation compared with non‐pegylated interferon plus ribavirin (low certainty).
1 finding from 1 review
Sustained virological response · people with chronic hepatitis C
It is very uncertain whether peginterferon plus ribavirin changes sustained virological response compared with non‐pegylated interferon plus ribavirin (very low certainty).
1 finding from 1 review
Sustained virological response · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes sustained virological response (SVR) compared with standard peginterferon plus ribavirin treatment (very low certainty).
1 finding from 1 review
Relapse · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes relapse compared with standard peginterferon plus ribavirin treatment (very low certainty).
1 finding from 1 review
End of treatment response (ETR) · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes end of treatment response (ETR) compared with standard peginterferon plus ribavirin treatment (very low certainty).
1 finding from 1 review
Sustained virological response · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin
Extended peginterferon plus ribavirin treatment for 72 weeks may leads to higher sustained virological response (SVR) compared with standard peginterferon plus ribavirin treatment (low certainty).
1 finding from 1 review
Relapse · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin
Extended peginterferon plus ribavirin treatment for 72 weeks may leads to lower relapse rate compared with standard peginterferon plus ribavirin treatment (low certainty).
1 finding from 1 review
End of treatment response (ETR) · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin
Extended peginterferon plus ribavirin treatment for 72 weeks may leads to lower end of treatment response (ETR) compared with standard peginterferon plus ribavirin treatment (low certainty).
1 finding from 1 review
Adherance to treatment · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin or participants with detectable…
Extended peginterferon plus ribavirin treatment for 72 weeks probably leads to lower adherance to treatment compared with standard peginterferon plus ribavirin treatment (moderate certainty).
1 finding from 1 review